Page 81 - Amgen News Today

Objective To investigate whether use of glucagon-like peptide 1 (GLP1) receptor agonists is associated with increased risk of thyroid cancer. Design Scandinavian cohort study. Setting Denmark, Norway, and Sweden, 2007-21. Participants Patients who started GLP1 receptor agonist treatment were compared with patients who started dipeptidyl peptidase 4 (DPP4) inhibitor treatment, and in an additional analysis, patients who started sodium-glucose cotransporter 2 (SGLT2) inhibitor treatment. Main outc...

As the man who made Jeffery Epstein professionally, the longtime head of Victoria’s Secret stepped down from his retail giant, seemingly finished. This is the inside story of how the 86-year-old quietly engineered one of the biggest semiconductor projects in history.

Kendall Capital Management lessened its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 3.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,621 shares of the medical research company’s stock after selling 170 shares during the period. Kendall […]

Locations are eager to attract companies in the life sciences industry by meeting their needs for educated workers and access to resources.

In a review, investigators focused on ranibizumab (Lucentis; Genentech), aflibercept (Eylea; Regeneron), and bevacizumab (Avastin; Genentech) as growth opportunities in the biosimilar space.

Chakravarthy explained, "This space around data management... it's powering a lot of these new generations of AI-powered intelligence." By providing a comprehensive platform for managing and analyzing data, Informatica enables companies to derive actionable insights and gain a competitive edge in today's data-driven economy.

Daily roundup of research and analysis from The Globe and Mail’s market strategist Scott Barlow

Strategic Blueprint LLC boosted its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 1.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,600 shares of the medical research company’s stock after purchasing an additional 55 shares during the period. Strategic Blueprint […]

In this article, we discuss 11 best biotech ETFs to buy. If you want to skip our discussion on the biotech industry, head over to 5 Best Biotech ETFs To Buy. The new era in biotech is defined by the convergence of biology, data, and artificial intelligence. According to The Journal of mHealth, the focus […]

Rainsberger Wealth Advisors Inc. acquired a new stake in Amgen Inc. (NASDAQ:AMGN – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 2,390 shares of the medical research company’s stock, valued at approximately $688,000. Other hedge funds also recently made changes […]